Cancer treatment reviews最新文献

{"title":"Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody–Drug conjugates","authors":"Yuwei Li ,&nbsp;Kaiyan Chen ,&nbsp;Hui Li ,&nbsp;Yun Fan","doi":"10.1016/j.ctrv.2026.103091","DOIUrl":"10.1016/j.ctrv.2026.103091","url":null,"abstract":"<div><div>Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour with a poor prognosis. Although treatment regimens such as first-line immunochemotherapy have shown clinical benefits in extensive stage SCLC (ES-SCLC), patients still face disease recurrence and drug resistance. Antibody-drug conjugates (ADCs) are new therapeutic compounds made up of a monoclonal antibody (mAb) attached to a cytotoxic drug (payload) using a linker. They achieve precise killing of tumour cells by conjugating highly cytotoxic drugs with monoclonal antibodies targeting specific tumour antigens. In recent years, antigens such as B7-H3, Trop-2, SEZ6, DLL3, and EGFR–HER3 have become primary targets for ADC development in ES-SCLC. Although some ADCs have been limited due to toxicity-related issues, numerous other ADCs have entered clinical trial phases and demonstrated encouraging efficacy, with ORRs of 33.3 %–68.0 % and median PFS of 4.0–7.6 months. In this review, we systematically summarize ADCs currently in clinical trials and preclinical research for SCLC, and comprehensively discuss their pharmacodynamic characteristics, therapeutic effects, adverse effects, and strategies for optimising treatment.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103091"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis","authors":"Kadriye Bir Yucel ,&nbsp;Yusuf Ilhan ,&nbsp;Elvina Almuradova ,&nbsp;Murat Bardakci ,&nbsp;Cigdem Dinckal ,&nbsp;Yakup Ergun","doi":"10.1016/j.ctrv.2025.103074","DOIUrl":"10.1016/j.ctrv.2025.103074","url":null,"abstract":"<div><h3>Background</h3><div>Human epidermal growth factor receptor 2 (HER2) overexpression defines a distinct breast cancer (BC) subtype that is highly sensitive to anti-HER2 therapy. However, the predictive and prognostic value of varying HER2 expression levels—specifically immunohistochemistry (IHC) 3 + versus IHC 2+/in situ hybridization (ISH)–positive—tumors remains uncertain. This systematic review and <em>meta</em>-analysis compared pathological complete response (pCR) between these subgroups in early-stage HER2-positive BC treated with anti-HER2–based neoadjuvant chemotherapy (NACT).</div></div><div><h3>Methods</h3><div>Following PRISMA guidelines (PROSPERO: CRD420251066320), PubMed, EMBASE, Cochrane Library, and ClinicalTrials databases were searched up to June 2025. Eligible studies compared HER2 (3 + ) and HER2 (2 + )/ISH + early-stage BC receiving anti-HER2–based NACT. Data extraction was performed independently by two reviewers. Pooled odds ratios (ORs) and hazard ratios (HRs) were calculated using fixed- or random-effects models according to heterogeneity.</div></div><div><h3>Results</h3><div>Thirteen retrospective studies involving 7,206 patients were included. Among 6,081 HER2-positive cases, 76 % were HER2 (3 + ) and 24 % were HER2 (2 + )/ISH + . The pooled pCR rate was significantly higher in HER2 (3 + ) tumors than in HER2 (2 + )/ISH + tumors (55.1 % vs. 21.6 %; OR = 5.38, 95 % CI: 3.72–7.80; p &lt; 0.00001). The difference persisted in dual-targeted regimens (66.0 % vs. 32.9 %; OR = 4.31, 95 % CI: 2.70–6.88; p &lt; 0.00001). No significant difference was observed in 3-year invasive disease-free survival (HR = 0.71, 95 % CI: 0.32–1.57; p = 0.40).</div></div><div><h3>Conclusion</h3><div>HER2 IHC 3 + tumors are substantially more likely to achieve pCR following anti-HER2–based NACT than HER2 (2 + )/ISH + tumors, indicating that HER2 expression intensity has predictive relevance. Quantitative HER2 assessment should be integrated into therapeutic planning and trial stratification to optimize outcomes in early-stage HER2-positive BC.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103074"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145922951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex vivo drug screening on patient-derived tumor material to advance functional precision in oncology: an overview on current approaches and unresolved challenges","authors":"Zoltán Spiró ,&nbsp;Amin El-Heliebi ,&nbsp;Maximilian J. Mair ,&nbsp;Thomas R. Pieber ,&nbsp;Barbara Prietl ,&nbsp;Sabine Spiegl-Kreinecker ,&nbsp;Stefanie Stanzer ,&nbsp;Adelheid Wöhrer ,&nbsp;Matthias Preusser ,&nbsp;Anna Sophie Berghoff","doi":"10.1016/j.ctrv.2025.103072","DOIUrl":"10.1016/j.ctrv.2025.103072","url":null,"abstract":"<div><div>The advent of mutation-informed targeted therapies has transformed medical oncology, delivering durable responses in several cancer types. However, this success has not been universal. Tumors such as glioblastoma have largely remained unresponsive to genomics-guided personalized treatments, and in many cancers, the correlation between genetic alterations and therapeutic response remains inconsistent.</div><div>To address these limitations, functional precision oncology − based on <em>ex vivo</em> drug screening using patient-derived tumor cells − has emerged as a compelling complementary approach. By directly testing drug responses in tumor cells, this strategy seeks to bypass the shortcomings of purely genomic prediction models, particularly in malignancies that have proven refractory to current targeted approaches.</div><div>This review outlines the state-of-the-art methodologies for patient-derived cell-based drug screening, examining their application across various tumor types and highlighting the current challenges and opportunities in implementing functional precision medicine in clinical oncology.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103072"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145879863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review","authors":"Noora Jatan ,&nbsp;Sami Talo ,&nbsp;Aida J. Azar ,&nbsp;Thomas E. Adrian ,&nbsp;Catherine F. Kellett","doi":"10.1016/j.ctrv.2025.103075","DOIUrl":"10.1016/j.ctrv.2025.103075","url":null,"abstract":"<div><h3>Background</h3><div>Aromatase inhibitors anastrozole and letrozole (non-steroidal, reversible), and exemestane (steroidal, irreversible) are approved standard therapies (Food and Drug Administration) for hormone receptor–positive breast cancer. Their use is limited by Aromatase Inhibitor-induced Musculoskeletal Signs and Symptoms (AIMSS).</div></div><div><h3>Methods</h3><div>Articles on AIMSS mechanisms and biomarkers published between January 1, 1990, and October 31, 2024, in PubMed, EMBASE, and Cochrane Library were identified. Included study designs were randomized and non-randomized trials, observational cohorts, cross-sectional studies, and preclinical animal models. Risk of bias was assessed using the Critical Appraisal Skills Programme tool for observational studies and Risk of Bias 2 for randomized trials.</div></div><div><h3>Results</h3><div>Fifty studies were included (43 human and seven animal). Estrogen deprivation was the central mechanism, affecting immune function, bone remodeling, and nociceptive sensitivity. Genetic variants in Estrogen Receptor 1, <em>CYP19A1</em>, and T-cell Leukemia/Lymphoma 1A were frequently associated with AIMSS. Vitamin D deficiency, polymorphisms in RANKL and Osteoprotegerin contributed to bone-related symptoms. Imaging studies identified tenosynovial thickening, tendon sheath fluid, and subclinical inflammation. Systemic inflammatory markers C-Reactive Protein and Interleukin 6 were elevated in human and animal studies.</div><div>Transient Receptor Potential Ankyrin 1 and Transient Receptor Potential Vanilloid 4 ion channels were implicated in peripheral sensitization. Insulin-like Growth Factor 1 during AI therapy was independently associated with symptoms.</div></div><div><h3>Conclusion</h3><div>AIMSS involves intersecting hormonal, genetic, inflammatory, and neural pathways. Identification of mechanistic biomarkers may support AIMSS risk stratification and targeted interventions. Further research should validate multi-omic models and explore new strategies to reduce AIMSS and improve treatment compliance.</div></div><div><h3>Registration</h3><div>PROSPERO Registration: CRD42025642540.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103075"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145922950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking endpoints for the watch-and-wait strategy in rectal cancer","authors":"Bartłomiej Skrzypiec,&nbsp;Agnieszka Żółciak-Siwińska,&nbsp;Lucyna Pietrzak,&nbsp;Krzysztof Bujko","doi":"10.1016/j.ctrv.2026.103087","DOIUrl":"10.1016/j.ctrv.2026.103087","url":null,"abstract":"<div><h3>Introduction</h3><div>To enable cross-trial comparisons of the benefit-risk ratio of the watch-and- wait strategy, two endpoints are required: a primary to assess the benefit and a co-primary to assess the main risk, i.e. regrowth.</div></div><div><h3>Material and methods</h3><div>We performed a literature search to identify and critically analyse endpoints used to evaluate the watch-and-wait strategies.</div></div><div><h3>Results and discussion</h3><div>The review identified four watch-and-wait strategy-specific primary endpoints assessing benefit and four methods for calculating regrowth rate across nine prospective studies, indicating the need for standardisation. To initiate a debate on this topic, we discuss shortcomings of the following commonly used endpoints: 1) “The clinical complete response (cCR) rate” is flawed for demonstrating benefit, as it combines patients who ultimately achieve sustained cCR (‘winners’) with those who eventually experience regrowth (‘losers’); 2) “the organ preservation rate” combines two procedures with different outcomes: watch-and-wait strategy and local excision; 3) calculating “the regrowth rate” only among patients achieving cCR—while excluding those with near-cCR who pursue watch-and-wait but later require surgery for persistent or progressive abnormalities—leads to an underestimation of the risk associated with deferring surgery. The following endpoints do not share these limitations and are therefore proposed for consideration in the debate on standardisation: 1) proportion of patients with sustained cCR among those who start radio(chemo)therapy; 2) the calculation of regrowth rate among pooled patients with cCR and all with near-cCR pursuing watch-and-wait surveillance.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103087"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145919264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring resistance to immune checkpoints inhibitors in mismatch repair-deficient or microsatellite-instable colorectal cancer","authors":"Clara Salva de Torres ,&nbsp;Evelyn Elias ,&nbsp;Caterina Vaghi ,&nbsp;Nadia Saoudi González ,&nbsp;Ariadna García ,&nbsp;Adriana Alcaraz ,&nbsp;Marta Rodríguez-Castells ,&nbsp;Iosune Baraibar ,&nbsp;Javier Ros ,&nbsp;Francesc Salvà ,&nbsp;Josep Tabernero ,&nbsp;Elena Élez ,&nbsp;Enrique Sanz-Garcia","doi":"10.1016/j.ctrv.2026.103089","DOIUrl":"10.1016/j.ctrv.2026.103089","url":null,"abstract":"<div><div>Colorectal cancer (CRC) with mismatch-repair deficiency (dMMR) or high microsatellite instability (MSI-H) represents a distinct molecular subtype highly sensitive to immune checkpoint inhibitors (ICIs). Landmark clinical trials have established ICIs as standard-of-care in this setting, demonstrating durable responses and improved survival. However, up to one-third of patients will exhibit primary or acquired resistance, highlighting the urgent need for predictive biomarkers and novel therapeutic strategies. This review summarizes the clinical evidence supporting ICIs in dMMR/MSI-H CRC, explores mechanisms of resistance—including intrinsic and extrinsic modulators—and evaluates the role of potential predictive biomarkers of response. Finally, we discuss innovative therapeutic approaches to overcome resistance, including combination strategies, DNA repair pathway inhibitors, immune-oncology drugs beyond checkpoint inhibitors and microbiome-targeted interventions. Together, these insights aim to refine patient selection, optimize therapeutic benefit, and guide the development of next-generation therapies for dMMR/MSI-H CRC.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103089"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KELIM score: A marker of chemosensitivity in ovarian cancer","authors":"Federica Adele Ambrosino ,&nbsp;Carmela Pisano ,&nbsp;Marilena Di Napoli ,&nbsp;Jole Ventriglia ,&nbsp;Rosa Tambaro ,&nbsp;Sabrina Rossetti ,&nbsp;Anna Passarelli ,&nbsp;Ernesta Cavalcanti ,&nbsp;Rossella De Cecio ,&nbsp;Francesco Fiore ,&nbsp;Sergio Venanzio Setola ,&nbsp;Teresa Troiani ,&nbsp;Lorenzo Lobianco ,&nbsp;Erica Perri ,&nbsp;Mariarosaria Lamia ,&nbsp;Gabriele Calvanese ,&nbsp;Sandro Pignata ,&nbsp;Sabrina Chiara Cecere","doi":"10.1016/j.ctrv.2025.103071","DOIUrl":"10.1016/j.ctrv.2025.103071","url":null,"abstract":"<div><div>Ovarian cancer is the gynecological cancer with the worst prognosis and the highest mortality rate, primarily because 75% of patients are diagnosed with advanced FIGO stage III-IV disease. About 50% of patients are now treated with neoadjuvant chemotherapy followed by interval debulking surgery. In that context, there is a need for accurate predictors of tumor primary chemosensitivity, as it may impact the feasibility of subsequent interval debulking surgery. The cancer antigen 125 ELIMination rate constant K (KELIM) score, a modeled kinetic parameter, is a potential marker of tumor chemosensitivity in patients with ovarian cancer treated with adjuvant or neoadjuvant chemotherapy before interval debulking surgery. This review aims to provide a comprehensive overview of potential predictive factors for response to platinum therapy, focusing on the KELIM score, a marker increasingly used in clinical practice.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103071"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2– advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials","authors":"Najwaa Kirmani ,&nbsp;Nathalia De León-Fernández ,&nbsp;Juan David Rodriguez-Parra ,&nbsp;Laura Ghanem ,&nbsp;Bezalel Hakkeem ,&nbsp;Clara Briceño-Morales ,&nbsp;Ximena Briceño-Morales","doi":"10.1016/j.ctrv.2026.103093","DOIUrl":"10.1016/j.ctrv.2026.103093","url":null,"abstract":"<div><h3>Background</h3><div>Endocrine therapy (ET) plus CDK4/6 inhibitors (CDK4/6i) remains first-line (1 L) standard for ER+/HER2– metastatic breast cancer (mBC). However, <em>ESR1</em> mutations lead to ET resistance and subsequent disease progression (PD). Limitations of intramuscular fulvestrant have led to the development of novel oral selective estrogen receptor degraders (SERDs). We aim to evaluate efficacy and safety of novel oral SERDs for ER+/HER2– mBC.</div></div><div><h3>Methods</h3><div>PubMed, Embase, and Cochrane were systematically searched for randomized controlled trials (RCTs) comparing oral SERDs with standard treatment. Primary outcomes were progression-free survival (PFS) overall and by subgroups (<em>ESR1</em> mutation, menopausal status, age, prior CDK4/6i use, visceral metastases), PFS comparing oral SERDs versus fulvestrant in <em>ESR1</em>-mutated patients, and grade ≥ 3 or discontinuation due to treatment-related adverse events (TRAEs). Hazard and risk ratios (HRs/RRs) were pooled using random-effects models (RStudio 2025.09.2 + 418).</div></div><div><h3>Results</h3><div>Eight RCTs (n = 3,978) were included. Overall, PFS did not differ significantly between groups (HR 0.80; 95 % CI 0.62–1.04; <em>p = 0.09</em>). Statistically significant PFS subgroups included: <em>ESR1</em> mutation (HR 0.57; 95 % CI 0.45–0.73; <em>p &lt; 0.01</em>); prior CDK4/6i use (HR 0.68; 95 % CI 0.49–0.95; <em>p = 0.03</em>); visceral metastases (HR 0.78; 95 % CI 0.63–0.97; <em>p = 0.03</em>); age &lt; 65 years (HR 0.75; 95 % CI 0.60–0.92; <em>p = 0.01</em>); and oral SERDs versus fulvestrant (HR 0.55; 95 % CI 0.46–0.66; <em>p &lt; 0.01</em>). Grade ≥ 3 TRAEs were higher with SERDs (RR 1.64; 95 % CI 1.07–2.50; <em>p = 0.03</em>), while treatment discontinuation was not significant.</div></div><div><h3>Conclusions</h3><div>Novel oral SERDs may represent a paradigm shift in managing PD after 1 L therapy, showing potential to improve PFS in selected patients.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103093"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?","authors":"Seng Wee Cheo ,&nbsp;Molly S.C. Li ,&nbsp;Derek De-Rui Huang ,&nbsp;Stephanie P.L. Saw ,&nbsp;Lizza E.L. Hendriks ,&nbsp;Jordi Remon ,&nbsp;Jessica Menis ,&nbsp;Alfredo Addeo ,&nbsp;Pei Jye Voon","doi":"10.1016/j.ctrv.2025.103083","DOIUrl":"10.1016/j.ctrv.2025.103083","url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) represent a rapidly evolving class of therapeutics in non-small cell lung cancer (NSCLC), offering targeted delivery of cytotoxic payloads to tumor cells while minimizing off-target toxicity. Although ADCs have demonstrated promising results in NSCLC, their efficacy in treating central nervous system (CNS) metastases has been uncertain due to concerns over blood–brain barrier (BBB) penetration and the lack of dedicated CNS-specific evaluations in clinical trials. However, emerging evidence challenges this paradigm. While earlier-generation ADCs such as T-DM1 exhibited limited CNS efficacy, newer ADCs employing optimized linkers and cytotoxins demonstrate more favorable efficacy and toxicity profiles. Selected agents, including trastuzumab deruxtecan, datopotamab deruxtecan and patritumab deruxtecan, have all shown intracranial responses in patients with advanced NSCLC with brain metastases (BM). Proposed mechanisms facilitating CNS activity include BBB disruption by BM, membrane-permeable and highly potent cytotoxic payloads, and bystander effects that enable tumor cell killing beyond the target antigen. Nevertheless, several limitations remain, including variability in trial designs, limited number of patients with untreated CNS disease, and a lack of CNS-specific endpoints. Given the high incidence of BM in NSCLC and their significant impact on patient outcomes, there is an urgent need to better understand the intracranial activity of ADCs and whether they can prevent the development of CNS metastases, especially as some of these ADCS are being tested in the curative-intent setting. This review synthesizes current evidence and highlights ongoing trials, with a focused examination of the evolving role of ADCs in the management of BM.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"143 ","pages":"Article 103083"},"PeriodicalIF":10.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145882443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AMH as a marker for resumption of ovarian function after chemotherapy: an IPD meta-analysis and systematic review","authors":"Charissa van Zwol – Janssens ,&nbsp;Mandy van M. Rosmalen ,&nbsp;Joop S.E. Laven ,&nbsp;Kazem Nasserinejad ,&nbsp;Jenny A. Visser ,&nbsp;Richard A. Anderson ,&nbsp;Irit Ben-Aharon ,&nbsp;Thomas Freour ,&nbsp;Kathryn J. Ruddy ,&nbsp;H. Irene Su ,&nbsp;Yvonne V. Louwers ,&nbsp;Agnes Jager","doi":"10.1016/j.ctrv.2025.103068","DOIUrl":"10.1016/j.ctrv.2025.103068","url":null,"abstract":"<div><h3>Background</h3><div>In premenopausal women with breast cancer, chemotherapy often leads to amenorrhea that could be temporary or permanent. Anti-Müllerian hormone (AMH) is a potential biomarker predicting resumption of ovarian function, an outcome that aids in the decision making for endocrine therapy. This study aimed to determine the predictive value of pre-chemotherapy AMH levels for resumption of ovarian function.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and individual patient data (IPD) meta-analysis. Online databases were searched using terms including: AMH, prediction, menses, menses recovery, amenorrhea, chemotherapy-related amenorrhea, anovulation, menopause, infertility, ovarian reserve, premenopausal, breast cancer, chemotherapy. The study protocol was registered with PROSPERO (CRD42021233966).</div></div><div><h3>Results</h3><div>The systematic review included 31 studies, with 26 contributing to the meta-analysis. Eleven studies provided IPD from 1,029 women. Ovarian function resumption rates varied from 24 % to 61 % depending on follow-up time. Pre-chemotherapy AMH was significantly higher in women whose ovarian function resumed, standardized mean difference 0.94 (95 % CI 0.65–1.22) and showed good predictive ability for resumption of ovarian function (AUC 0.79–0.83). However, the identified cut-off values for pre-chemotherapy AMH gave high false negative rates and differed a lot between studies which was much determined by follow-up time, age and used AMH assay.</div></div><div><h3>Conclusion</h3><div>Pre-chemotherapy AMH shows association with ovarian function resumption, but a clinically reliable cut-off across assays could not be established using individual patient data. Therefore, due to high inter-assay variability, AMH is not suitable for optimizing endocrine therapy in premenopausal breast cancer patients at this time. Standardizing AMH assays can help in further research into a cut-off value.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"142 ","pages":"Article 103068"},"PeriodicalIF":10.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145835417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}